The prodrug platin-A: Simultaneous release of cisplatin and aspirin

Rakesh K. Pathak, Sean Marrache, Joshua H. Choi, Trenton B. Berding, Shanta Dhar

Research output: Contribution to journalArticle

134 Citations (Scopus)

Abstract

Cancer-associated inflammation induces tumor progression to the metastatic stage, thus indicating that a chemo-anti-inflammatory strategy is of interest for the management of aggressive cancers. The platinum(IV) prodrug Platin-A was designed to release cisplatin and aspirin to ameliorate the nephrotoxicity and ototoxicity caused by cisplatin. Platin-A exhibited anticancer and anti-inflammatory properties which are better than a combination of cisplatin and aspirin. These findings highlight the advantages of combining anti-inflammatory treatment with chemotherapy when both the drugs are delivered in the form of a single prodrug. The prodrug Platin-A was designed to release cisplatin and aspirin to ameliorate the side effects of cisplatin. Platin-A exhibits anticancer and anti-inflammatory properties which are better than those for the combined use of cisplatin and aspirin. These findings highlight the advantages of combining anti-inflammatory treatment with chemotherapy when both the drugs are delivered as a single prodrug.

Original languageEnglish (US)
Pages (from-to)1963-1967
Number of pages5
JournalAngewandte Chemie - International Edition
Volume53
Issue number7
DOIs
StatePublished - Feb 10 2014
Externally publishedYes

Fingerprint

Chemotherapy
Prodrugs
Cisplatin
Aspirin
Anti-Inflammatory Agents
Tumors
Platinum
Pharmaceutical Preparations

Keywords

  • antitumor agents
  • drug design
  • inflammation
  • platinum
  • prodrugs

ASJC Scopus subject areas

  • Catalysis
  • Chemistry(all)

Cite this

The prodrug platin-A : Simultaneous release of cisplatin and aspirin. / Pathak, Rakesh K.; Marrache, Sean; Choi, Joshua H.; Berding, Trenton B.; Dhar, Shanta.

In: Angewandte Chemie - International Edition, Vol. 53, No. 7, 10.02.2014, p. 1963-1967.

Research output: Contribution to journalArticle

Pathak, Rakesh K. ; Marrache, Sean ; Choi, Joshua H. ; Berding, Trenton B. ; Dhar, Shanta. / The prodrug platin-A : Simultaneous release of cisplatin and aspirin. In: Angewandte Chemie - International Edition. 2014 ; Vol. 53, No. 7. pp. 1963-1967.
@article{02e1c2603dd5490d8c1e8c79ccda5b97,
title = "The prodrug platin-A: Simultaneous release of cisplatin and aspirin",
abstract = "Cancer-associated inflammation induces tumor progression to the metastatic stage, thus indicating that a chemo-anti-inflammatory strategy is of interest for the management of aggressive cancers. The platinum(IV) prodrug Platin-A was designed to release cisplatin and aspirin to ameliorate the nephrotoxicity and ototoxicity caused by cisplatin. Platin-A exhibited anticancer and anti-inflammatory properties which are better than a combination of cisplatin and aspirin. These findings highlight the advantages of combining anti-inflammatory treatment with chemotherapy when both the drugs are delivered in the form of a single prodrug. The prodrug Platin-A was designed to release cisplatin and aspirin to ameliorate the side effects of cisplatin. Platin-A exhibits anticancer and anti-inflammatory properties which are better than those for the combined use of cisplatin and aspirin. These findings highlight the advantages of combining anti-inflammatory treatment with chemotherapy when both the drugs are delivered as a single prodrug.",
keywords = "antitumor agents, drug design, inflammation, platinum, prodrugs",
author = "Pathak, {Rakesh K.} and Sean Marrache and Choi, {Joshua H.} and Berding, {Trenton B.} and Shanta Dhar",
year = "2014",
month = "2",
day = "10",
doi = "10.1002/anie.201308899",
language = "English (US)",
volume = "53",
pages = "1963--1967",
journal = "Angewandte Chemie - International Edition",
issn = "1433-7851",
publisher = "John Wiley and Sons Ltd",
number = "7",

}

TY - JOUR

T1 - The prodrug platin-A

T2 - Simultaneous release of cisplatin and aspirin

AU - Pathak, Rakesh K.

AU - Marrache, Sean

AU - Choi, Joshua H.

AU - Berding, Trenton B.

AU - Dhar, Shanta

PY - 2014/2/10

Y1 - 2014/2/10

N2 - Cancer-associated inflammation induces tumor progression to the metastatic stage, thus indicating that a chemo-anti-inflammatory strategy is of interest for the management of aggressive cancers. The platinum(IV) prodrug Platin-A was designed to release cisplatin and aspirin to ameliorate the nephrotoxicity and ototoxicity caused by cisplatin. Platin-A exhibited anticancer and anti-inflammatory properties which are better than a combination of cisplatin and aspirin. These findings highlight the advantages of combining anti-inflammatory treatment with chemotherapy when both the drugs are delivered in the form of a single prodrug. The prodrug Platin-A was designed to release cisplatin and aspirin to ameliorate the side effects of cisplatin. Platin-A exhibits anticancer and anti-inflammatory properties which are better than those for the combined use of cisplatin and aspirin. These findings highlight the advantages of combining anti-inflammatory treatment with chemotherapy when both the drugs are delivered as a single prodrug.

AB - Cancer-associated inflammation induces tumor progression to the metastatic stage, thus indicating that a chemo-anti-inflammatory strategy is of interest for the management of aggressive cancers. The platinum(IV) prodrug Platin-A was designed to release cisplatin and aspirin to ameliorate the nephrotoxicity and ototoxicity caused by cisplatin. Platin-A exhibited anticancer and anti-inflammatory properties which are better than a combination of cisplatin and aspirin. These findings highlight the advantages of combining anti-inflammatory treatment with chemotherapy when both the drugs are delivered in the form of a single prodrug. The prodrug Platin-A was designed to release cisplatin and aspirin to ameliorate the side effects of cisplatin. Platin-A exhibits anticancer and anti-inflammatory properties which are better than those for the combined use of cisplatin and aspirin. These findings highlight the advantages of combining anti-inflammatory treatment with chemotherapy when both the drugs are delivered as a single prodrug.

KW - antitumor agents

KW - drug design

KW - inflammation

KW - platinum

KW - prodrugs

UR - http://www.scopus.com/inward/record.url?scp=84893537386&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893537386&partnerID=8YFLogxK

U2 - 10.1002/anie.201308899

DO - 10.1002/anie.201308899

M3 - Article

C2 - 24453035

AN - SCOPUS:84893537386

VL - 53

SP - 1963

EP - 1967

JO - Angewandte Chemie - International Edition

JF - Angewandte Chemie - International Edition

SN - 1433-7851

IS - 7

ER -